Skip to content

Precigen PGEN Operating Income

Operating Income at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$642.9M+8.7%
Gilead Sciences logo
Gilead SciencesGILD
$2.59B+15.6%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-$116.17M-23.8%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
-$110.03M-3.2%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
-$82.77M-31.2%
Arrowhead Research logo
Arrowhead ResearchARWR
-$141.26M-137%

Other financials

Income statement

See full
Revenue$23.3M+1,634%
Net income-$7.9M+85.4%
EPS (diluted)-$0.02+88.9%

Balance sheet

See full
Cash & equivalents$7.5M+23.5%
Total debt$98.3M+1,714%
Total equity$20.2M+244%
Total assets$138.6M+7.6%

Cash flow

See full
Operating cash flow-$43.8M-168%
CapEx$258.0K-58.5%
Free cash flow-$44.1M-160%

Valuation

See full
Market cap$1.91B+213%
Enterprise value$2B+234%
P/S72×

Profitability

See full
Gross margin83.6%
Operating margin-2,890.9%
Net margin-3,656%
FCF margin-1,756.5%

Returns & leverage

See full
Return on equity-843.6%-1,103pp
Debt / equity4.9×
Current ratio4.8×+1.3×

Where this comes from

Reported directly by Precigen in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The official record: Precigen’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Precigen's operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Precigen's operating income?
Precigen (PGEN) reported operating income of -$5.99M in Q1 2026.
How has Precigen's operating income changed year-over-year?
Precigen's operating income increased by 73.5% year-over-year, from -$22.6M to -$5.99M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.